NO954778D0 - Ekspresjon av urokinase plasminogen aktivator inhibitorer - Google Patents

Ekspresjon av urokinase plasminogen aktivator inhibitorer

Info

Publication number
NO954778D0
NO954778D0 NO954778A NO954778A NO954778D0 NO 954778 D0 NO954778 D0 NO 954778D0 NO 954778 A NO954778 A NO 954778A NO 954778 A NO954778 A NO 954778A NO 954778 D0 NO954778 D0 NO 954778D0
Authority
NO
Norway
Prior art keywords
expression
plasminogen activator
urokinase plasminogen
activator inhibitors
hupar
Prior art date
Application number
NO954778A
Other languages
English (en)
Norwegian (no)
Other versions
NO954778L (no
Inventor
Steven Rosenberg
Jennifer R Stratton-Thomas
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of NO954778D0 publication Critical patent/NO954778D0/no
Publication of NO954778L publication Critical patent/NO954778L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00041—Use of virus, viral particle or viral elements as a vector
    • C12N2795/00043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
NO954778A 1993-06-01 1995-11-24 Ekspresjon av urokinase plasminogen aktivator inhibitorer NO954778L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7015393A 1993-06-01 1993-06-01
PCT/US1994/005669 WO1994028145A2 (fr) 1993-06-01 1994-05-19 Expression d'inhibiteurs de l'activateur de l'urokinase-plasminogene

Publications (2)

Publication Number Publication Date
NO954778D0 true NO954778D0 (no) 1995-11-24
NO954778L NO954778L (no) 1995-11-24

Family

ID=22093474

Family Applications (1)

Application Number Title Priority Date Filing Date
NO954778A NO954778L (no) 1993-06-01 1995-11-24 Ekspresjon av urokinase plasminogen aktivator inhibitorer

Country Status (12)

Country Link
US (1) US6268341B1 (fr)
EP (1) EP0802983B1 (fr)
JP (1) JPH08508172A (fr)
KR (1) KR960702522A (fr)
AT (1) ATE239085T1 (fr)
AU (1) AU7137994A (fr)
CA (1) CA2162855A1 (fr)
DE (1) DE69432608T2 (fr)
FI (1) FI955721A (fr)
NO (1) NO954778L (fr)
NZ (1) NZ268470A (fr)
WO (1) WO1994028145A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5519120A (en) * 1989-04-07 1996-05-21 Cancerforskningsfondet Af 1989 Urokinase-type plasminogen activator receptor antibodies
DE69432608T2 (de) 1993-06-01 2004-02-26 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Expression von inhibitoren vom plasminogenaktivator vom urokinasetyp
US5891742A (en) * 1995-01-19 1999-04-06 Chiron Corporation Affinity selection of ligands by mass spectroscopy
US6277818B1 (en) 1998-10-29 2001-08-21 Angstrom Pharmaceuticals, Inc. Cyclic peptide ligands that target urokinase plasminogen activator receptor
US5942492A (en) 1996-11-12 1999-08-24 Angstrom Pharmaceuticals, Inc. Cyclic peptides that bind to urokinase-type plasminogen activator receptor
US5994309A (en) 1997-07-25 1999-11-30 Angstrom Pharmaceuticals, Inc. Anti-invasive and anti-angiogenic compositions and methods
CA2306953A1 (fr) * 1997-10-17 1999-04-29 Abd Al-Roof Higazi Compositions et procedes permettant de favoriser l'internalisation et la degradation de l'activateur du plasminogene de type urokinase
US6750201B1 (en) 1997-10-17 2004-06-15 The Trustees Of The University Of Pennsylvania Compositions and methods for promoting internalization and degradation of urokinase-type plasminogen activator
US6423685B1 (en) * 1998-03-05 2002-07-23 Chiron Corporation Method for increasing the serum half-life of a biologically active molecule
US6077508A (en) * 1998-03-23 2000-06-20 American Diagnostica Inc. Urokinase plasminogen activator receptor as a target for diagnosis of metastases
US20030203032A1 (en) * 2002-04-25 2003-10-30 Schultz Clyde L. Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease
EP1503730A4 (fr) * 2002-04-25 2005-09-28 Rapidheal Inc Systeme d'administration d'un facteur de croissance servant a la cicatrisation de plaies et a la prevention d'inflammations et de maladies
US20050255144A1 (en) * 2003-04-09 2005-11-17 Directcontact Llc Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases
US9216106B2 (en) 2003-04-09 2015-12-22 Directcontact Llc Device and method for the delivery of drugs for the treatment of posterior segment disease
US20050074497A1 (en) * 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
US20050244472A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
TW200813091A (en) * 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112755A (en) 1982-04-15 1992-05-12 Genentech, Inc. Preparation of functional human urokinase proteins
US4870008A (en) * 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
US4880734A (en) 1984-05-11 1989-11-14 Chiron Corporation Eukaryotic regulatable transcription
US4791068A (en) 1984-06-22 1988-12-13 Scripps Clinic And Research Foundation Diagnostic assay for inhibitor of tissue-type and urokinase-type plasminogen activators
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
EP0218696A4 (fr) 1985-04-15 1989-08-16 Biotech Res Partners Ltd Proteine anti-inflammatoire d'inhibition de la phospholipase humaine.
US5219569A (en) 1985-04-22 1993-06-15 Genentech, Inc. Protease resistant urokinase
EP0299053A1 (fr) 1987-01-30 1989-01-18 American Home Products Corporation Activateurs du plasminogene du facteur de croissance des-epidermique
US4835255A (en) 1987-03-26 1989-05-30 Yale University T-cell membrane protein
US4999194A (en) 1988-01-14 1991-03-12 Collaborative Research, Inc. Two-chain urokinase plasminogen activators for treatment of thrombotic disease
DK182289D0 (da) 1989-04-14 1989-04-14 Francesco Blasi Modifikation af proteiner
ATE219791T1 (de) * 1990-10-18 2002-07-15 Cancerforskningsfonden Af 1989 Antikörper gegen den urokinaserezeptor und ihre verwendung
JPH0595786A (ja) 1991-10-07 1993-04-20 Green Cross Corp:The 変異ヒトプロウロキナーゼ
US5340833A (en) 1992-05-01 1994-08-23 Eisai Co., Ltd. Urokinase inhibitors
US6120765A (en) 1993-04-02 2000-09-19 Shiseido Co. Ltd. Urokinase plasminogen activator fragments
ATE182336T1 (de) 1993-05-28 1999-08-15 Chiron Corp Peptidinhibitoren der urokinaserezeptor-aktivität
DE69432608T2 (de) 1993-06-01 2004-02-26 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Expression von inhibitoren vom plasminogenaktivator vom urokinasetyp

Also Published As

Publication number Publication date
FI955721A0 (fi) 1995-11-27
NZ268470A (en) 1997-09-22
DE69432608T2 (de) 2004-02-26
EP0802983A2 (fr) 1997-10-29
KR960702522A (ko) 1996-04-27
JPH08508172A (ja) 1996-09-03
CA2162855A1 (fr) 1994-12-08
AU7137994A (en) 1994-12-20
US6268341B1 (en) 2001-07-31
EP0802983B1 (fr) 2003-05-02
WO1994028145A2 (fr) 1994-12-08
NO954778L (no) 1995-11-24
DE69432608D1 (de) 2003-06-12
ATE239085T1 (de) 2003-05-15
FI955721A (fi) 1995-11-27
WO1994028145A3 (fr) 1995-10-19

Similar Documents

Publication Publication Date Title
NO954778L (no) Ekspresjon av urokinase plasminogen aktivator inhibitorer
MY119155A (en) New peptide derivatives
GB8909919D0 (en) Small polypeptides
NZ309523A (en) Peptidyl heterocycles useful in the treatment of thrombin related disorders
TR199801151T2 (xx) Trombin inhibit�r� �n ila�lar.
DK0719154T3 (da) Aktiveret faktor VIII som terapeutisk middel og metode til behandling af faktor VIII-mangel
WO1994028014A3 (fr) Peptides inhibiteurs de l'activite des recepteurs d'urokinase
MX9706069A (es) Nuevos inhibidores de la trombina.
TNSN94105A1 (fr) Composes sulfonamides tricycliques utiles pour l'inhibition de la fonction proteine g et pour le traitement des maladies proliferatives
NZ248377A (en) Use of interleukin-1 beta protease and interleukin-1 beta protease inhibitors
NO961888D0 (no) Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer av metallproteinaser
MY111201A (en) New imidazopyridines
DE69034013D1 (de) Serpin-resistenter T-PA; Mutanten; Gene
AP9200410A0 (en) Retroviral protease inhibitors.
AU623769B2 (en) Proteinase inhibitors, process for the preparation thereof and medicaments containing these
DE60139078D1 (de) Plasminogen aktivator zur verhinderung von horn- und subepithelialeintrübung nach laser-sehkraftkorrektur-chirurgie
ES8604265A1 (es) Un metodo para preparar un peptido o una sal no toxica del mismo.
ES2145122T3 (es) Compuestos antiproliferantes de 5-tiapirimidinona y 5-selenopirimidinona sustituidos.
HK1016495A1 (en) Phosphorous-containing cysteine and serine protease inhibitors
UA27910C2 (uk) Засіб для підвищення експресії тромбомодуліну та підвищення активації протеїну с
DE69021885D1 (de) Mutanten des menschlichen plasminogenaktivator-inhibitors 1 (pai-1), ihre herstellung und verwendung.
UA27132C2 (uk) Двофуhкціоhальhі варіаhти урокіhази зі зміцнеhою фібриhолітичhою властивістю і тромбіh-іhгібуючою дією
MX9606494A (es) Compuestos organicos.
MX9709340A (es) Inhibidores de proteasa de serina derivados de imidazo (1,5a) piridina.
FI102844B1 (fi) Menetelmä valmistaa parannettu terapeuttisesti aktiivinen kudosplasminogeenin aktivaattori